Literature DB >> 21843107

The redesigned follitropin alfa pen injector: results of the patient and nurse human factors usability testing.

Joan C Schertz1, Helen Saunders, Clara Hecker, Barbara Lang, Pablo Arriagada.   

Abstract

OBJECTIVES: A redesigned pen injector for administration of follitropin alfa (follitropin α) has been developed for use in fertility treatment cycles. Pre-summative and summative usability testing was undertaken to assess the risk of dosing errors compared with the existing follitropin α pen. The study also assessed proper use of and dose selection with the redesigned pen.
METHODS: Infertile women who were trying to conceive and specialist nurses were recruited from four cities in Germany. Usability goals relating to proper use of the pen device were defined from a risk assessment and further categorized as critical and functional operational goals. Individual, non-interventional, standardized, usability tests were performed with patients and nurses by four experienced research professionals using questionnaires that also included ease-of-use ratings. A non-standardized qualitative analysis of nurse-patient training sessions was performed in the presence of a research professional; reasons for confidence, safety, possible misunderstandings and risks when handling the pen were noted.
RESULTS: The overall risk of dosing errors with the redesigned pen was not higher than with the existing pen. No unexpected operational risks and no major concerns regarding the risk of misuse or dosing errors were identified.
CONCLUSIONS: The study provides useful practical information on the redesigned pen from both patient and nurse perspectives.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21843107     DOI: 10.1517/17425247.2011.608350

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  5 in total

1.  Multicenter, noninterventional, post-marketing surveillance study to evaluate dosing of recombinant human follicle-stimulating hormone using the redesigned follitropin alfa pen in women undergoing ovulation induction.

Authors:  Frank Nawroth; Andreas Tandler-Schneider; Wilma Bilger
Journal:  Drug Healthc Patient Saf       Date:  2015-04-15

2.  Formative usability evaluation of a fixed-dose pen-injector platform device.

Authors:  Jakob Lange; Tobias Nemeth
Journal:  Med Devices (Auckl)       Date:  2018-04-04

3.  Usability of devices for self-injection: results of a formative study on a new disposable pen injector.

Authors:  Jakob Lange; Philipp Richard; Nick Bradley
Journal:  Med Devices (Auckl)       Date:  2014-06-12

4.  Single-arm, observational study of the ease of use of a redesigned pen device to deliver recombinant human follicle-stimulating hormone (follitropin alfa) for assisted reproductive technology treatment.

Authors:  Peter J Illingworth; Robert Lahoud; Frank Quinn; Kendal Chidwick; Claire Wilkinson; Gavin Sacks
Journal:  Patient Prefer Adherence       Date:  2014-06-05       Impact factor: 2.711

5.  Analysis of patient and nurse preferences for self-administered FSH injection devices in select European markets.

Authors:  Pierre Zitoun; Jaya Parikh; Martine Nijs; Wenjie Zhang; Rachel Levy-Toledano; Boxiong Tang
Journal:  Int J Womens Health       Date:  2019-01-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.